查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417743

GLP-1 受體促效劑市場報告：2030 年趨勢、預測與競爭分析

Glucagon-Like Peptide 1 Agonists Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

GLP-1受體促效劑的趨勢與預測

預計到 2030 年，GLP-1 受體促效劑的全球市場將達到約 251 億美元，2024 年至 2030 年的複合年成長率為 6.0%。這個市場的主要促進因素是第2型糖尿病、肥胖及相關疾病病例的增加、對不健康生活方式的適應程度的增加、糖尿病疾病的遺傳史以及人口老化的增加。 GLP-1受體促效劑的全球市場前景廣闊，醫院和專科診所市場充滿機會。

GLP-1 受體促效劑市場洞察

Lucintel 預測，由於肥胖率增加和第 2 型糖尿病遺傳風險因素增加，Dulaglutide在預測期內仍將是最大的細分市場。

由於研發的擴大和醫療設施的增加，北美在預測期內將繼續成為最大的地區。

常問問題

Q1.市場規模有多大？

A1.到2030年，GLP-1受體促效劑的全球市場預計將達到251億美元。

Q2.市場成長預測如何？

A2. 2024年至2030年，GLP-1受體促效劑的全球市場預計將以6.0%的複合年成長率成長。

Q3.影響市場成長的主要促進因素有哪些？

A3. 此市場的主要促進因素是第2型糖尿病、肥胖及相關疾病病例的增加、對不健康生活方式的適應程度的增加、糖尿病疾病的遺傳史以及人口老化的增加。

Q4.市場的主要細分市場是什麼？

A4.GLP-1受體促效劑全球市場前景廣闊，為醫院和專科診所提供市場機會。

Q5. 市場上主要企業有哪些？

A5.促效劑的主要企業如下。

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Astrazeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計，由於肥胖率增加和 2 型糖尿病遺傳風險因素增加，Dulaglutide在預測期內仍將是其最大的細分市場。

Q7. 未來五年預計哪個地區將成為最大的市場？

A7. 由於研發擴張和醫療設施增加，北美在預測期內將繼續成為最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球 GLP-1 受體促效劑市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球GLP-1受體促效劑市場趨勢（2018-2023）與預測（2024-2030）
  • 按藥物類型分類的全球 GLP-1 受體促效劑市場
    • Exenatide
    • Liraglutide
    • Lixisenatide
    • Dulaglutide
  • 全球 GLP-1 受體促效劑市場（依品牌）
    • 拜埃塔
    • 比杜隆
    • 維克托扎
    • 特魯利西蒂
    • 里克斯米爾
  • 依給藥途徑的全球 GLP-1 受體促效劑市場
    • 口服
    • 胃腸外的
    • 其他
  • 以最終用途分類的全球 GLP-1 受體促效劑市場
    • 醫院
    • 專科診所
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球GLP-1受體促效劑市場區域分佈
  • 北美GLP-1受體促效劑市場
  • 歐洲GLP-1受體促效劑市場
  • 亞太GLP-1受體促效劑市場
  • 其他地區GLP-1受體促效劑市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按藥物類型分類的全球 GLP-1 受體促效劑市場成長機會
    • 全球 GLP-1 受體促效劑市場成長機會（按品牌）
    • 按途徑分類的全球 GLP-1 受體促效劑市場成長機會
    • 全球 GLP-1 受體促效劑市場成長機會（依最終用途）
    • 全球 GLP-1 受體促效劑市場成長機會（按地區）
  • 全球GLP-1受體促效劑市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 全球 GLP-1 受體促效劑市場產能擴張
    • 全球GLP-1受體促效劑市場的併購與合資企業
    • 認證和許可

第7章主要企業概況

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan
簡介目錄

Glucagon-Like Peptide 1 Agonists Trends and Forecast

The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets. The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030 with a CAGR of 6.0% from 2024 to 2030. The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

A more than 150-page report is developed to help in your business decisions.

Glucagon-Like Peptide 1 Agonists by Segment

The study includes a forecast for the global glucagon-like peptide 1 agonists by drug type, brand, route of administration, end use, and region.

Glucagon-Like Peptide 1 Agonists Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Exenatide
  • Liraglutide
  • Lixisenatide
  • Dulaglutide

Glucagon-Like Peptide 1 Agonists Market by Brand [Shipment Analysis by Value from 2018 to 2030]:

  • Byetta
  • Bydureon
  • Victoza
  • Trulicity
  • Lyxumia

Glucagon-Like Peptide 1 Agonists Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral
  • Others

Glucagon-Like Peptide 1 Agonists Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Others

Glucagon-Like Peptide 1 Agonists Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Glucagon-Like Peptide 1 Agonists Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies glucagon-like peptide 1 agonists companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the glucagon-like peptide 1 agonists companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Astrazeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan

Glucagon-Like Peptide 1 Agonists Market Insights

Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Features of the Global Glucagon-Like Peptide 1 Agonists Market

Market Size Estimates: Glucagon-like peptide 1 agonists market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Glucagon-like peptide 1 agonists market size by various segments, such as by drug type, brand, route of administration, end use, and region in terms of value ($B).

Regional Analysis: Glucagon-like peptide 1 agonists market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug type, brand, route of administration, end use, and regions for the glucagon-like peptide 1 agonists market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the glucagon-like peptide 1 agonists market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the glucagon-like peptide 1 agonists market size?

Answer: The global glucagon-like peptide 1 agonists market is expected to reach an estimated $25.1 billion by 2030.

Q2. What is the growth forecast for glucagon-like peptide 1 agonists market?

Answer: The global glucagon-like peptide 1 agonists market is expected to grow with a CAGR of 6.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the glucagon-like peptide 1 agonists market?

Answer: The major drivers for this market are increase in the cases of type 2 diabetes, obesity and related disorders, increasing adaptation of unhealthy lifestyle and genetic history of diabetes disorders, as well as, growing aging population.

Q4. What are the major segments for glucagon-like peptide 1 agonists market?

Answer: The future of the global glucagon-like peptide 1 agonists market looks promising with opportunities in the hospital and specialty clinic markets.

Q5. Who are the key glucagon-like peptide 1 agonists market companies?

Answer: Some of the key glucagon-like peptide 1 agonists companies are as follows.

  • F. Hoffmann-La Roche
  • Bristol-Myers Squibb Company
  • Astrazeneca
  • Pfizer
  • Baxter
  • Hikma Pharmaceuticals
  • Amneal Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • Mylan

Q6. Which glucagon-like peptide 1 agonists market segment will be the largest in future?

Answer: Lucintel forecasts that dulaglutide will remain the largest segment over the forecast period due to growing obesity rates, and increasing genetic risk factors for type 2 diabetes.

Q7. In glucagon-like peptide 1 agonists market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the expansion of research and development, as well as growing healthcare facilities in the region.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the glucagon-like peptide 1 agonists market by drug type (exenatide, liraglutide, lixisenatide, and dulaglutide), brand (byetta, bydureon, victoza, trulicity, and lyxumia), route of administration (oral, parenteral, and others), end use (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Glucagon-Like Peptide 1 Agonists Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Glucagon-Like Peptide 1 Agonists Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
    • 3.3.1: Exenatide
    • 3.3.2: Liraglutide
    • 3.3.3: Lixisenatide
    • 3.3.4: Dulaglutide
  • 3.4: Global Glucagon-Like Peptide 1 Agonists Market by Brand
    • 3.4.1: Byetta
    • 3.4.2: Bydureon
    • 3.4.3: Victoza
    • 3.4.4: Trulicity
    • 3.4.5: Lyxumia
  • 3.5: Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
    • 3.5.1: Oral
    • 3.5.2: Parenteral
    • 3.5.3: Others
  • 3.6: Global Glucagon-Like Peptide 1 Agonists Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Glucagon-Like Peptide 1 Agonists Market by Region
  • 4.2: North American Glucagon-Like Peptide 1 Agonists Market
    • 4.2.2: North American Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.3: European Glucagon-Like Peptide 1 Agonists Market
    • 4.3.1: European Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
    • 4.3.2: European Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.4: APAC Glucagon-Like Peptide 1 Agonists Market
    • 4.4.1: APAC Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
    • 4.4.2: APAC Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others
  • 4.5: ROW Glucagon-Like Peptide 1 Agonists Market
    • 4.5.1: ROW Glucagon-Like Peptide 1 Agonists Market by Drug Type: Exenatide, Liraglutide, Lixisenatide, and Dulaglutide
    • 4.5.2: ROW Glucagon-Like Peptide 1 Agonists Market by End Use: Hospitals, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Brand
    • 6.1.3: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Route of Administration
    • 6.1.4: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by End Use
    • 6.1.5: Growth Opportunities for the Global Glucagon-Like Peptide 1 Agonists Market by Region
  • 6.2: Emerging Trends in the Global Glucagon-Like Peptide 1 Agonists Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Glucagon-Like Peptide 1 Agonists Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Glucagon-Like Peptide 1 Agonists Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Bristol-Myers Squibb Company
  • 7.3: AstraZeneca
  • 7.4: Pfizer
  • 7.5: Baxter
  • 7.6: Hikma Pharmaceuticals
  • 7.7: Amneal Pharmaceuticals
  • 7.8: Teva Pharmaceuticals
  • 7.9: Sun Pharmaceuticals
  • 7.10: Mylan